Lymphoma, B-Cell: all 1,415 studies
Page 5 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT03123393Phase 2Results posted
- Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasActive, not recruitingNCT03038672Phase 2Results posted
- Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor PatientsCompletedNCT03028103Phase 1Results posted
- Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell LymphomaCompletedNCT03023878Phase 2Results posted
- Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT03019640Phase 2Results posted
- Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B CellCompletedNCT03019055Phase 1Results posted
- A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT03009344Phase 1Results posted
- A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell LymphomaCompletedNCT03003520Phase 2Results posted
- Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell TransplantationCompletedNCT02981914Early Phase 1Results posted
- Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaTerminatedNCT02953509Phase 1/2Results posted
- Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)TerminatedNCT02951156Phase 3Results posted
- BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or LeukaemiaCompletedNCT02933320Phase 1/2Results posted
- Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02926833Phase 1/2Results posted
- Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell LymphomaActive, not recruitingNCT02911142Phase 1/2Results posted
- Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHLCompletedNCT02910063Phase 2/3Results posted
- Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell LymphomaTerminatedNCT02898259Phase 1/2Results posted
- TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02874404Phase 2Results posted
- DA-EPOCH-Rituximab/Metformin (RM) for Double Hit LymphomaTerminatedNCT02815397Phase 2Results posted
- A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02760485Phase 1/2Results posted
- JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT02706405Phase 1Results posted
- A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin LymphomaTerminatedNCT02703272Phase 3Results posted
- Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCTCompletedNCT02692248Phase 2Results posted
- Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC AlterationsCompletedNCT02674750Phase 2Results posted
- T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell MalignanciesCompletedNCT02659943Phase 1Results posted
- Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)CompletedNCT02658968Phase 1Results posted
- Smart Start: A Phase II Study of Rituximab, Lenalidomide, and IbrutinibCompletedNCT02636322Phase 2Results posted
- R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT02628405Phase 1/2Results posted
- MabionCD20 Compared to MabThera in Lymphoma PatientsCompletedNCT02617485Phase 3Results posted
- A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02600897Phase 1/2Results posted
- 18F-FSPG PET/CT for Cancer Patients on TherapyCompletedNCT02599194Phase 2Results posted
- A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02596971Phase 1/2Results posted
- Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell LymphomaTerminatedNCT02594163Phase 2Results posted
- Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaTerminatedNCT02592876Phase 2Results posted
- Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC SubtypeTerminatedNCT02589145Phase 1/2Results posted
- Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)CompletedNCT02576990Phase 2Results posted
- Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCLTerminatedNCT02572453Phase 2Results posted
- Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)TerminatedNCT02568683Phase 1/2Results posted
- Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHLCompletedNCT02564744Phase 2Results posted
- Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular LymphomaCompletedNCT02541565Phase 1Results posted
- Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)TerminatedNCT02531308Phase 2Results posted
- Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First RemissionTerminatedNCT02530125Phase 2Results posted
- A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell LymphomaCompletedNCT02529852Phase 1/2Results posted
- GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's LymphomaTerminatedNCT02495454Phase 2Results posted
- MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell LymphomaCompletedNCT02486952Results posted
- Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell MalignanciesTerminatedNCT02483000Phase 1Results posted
- Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin LymphomaStatus unknownNCT02481310Phase 1/2Results posted
- Study of Efficacy and Safety of CTL019 in Adult DLBCL PatientsCompletedNCT02445248Phase 2Results posted
- A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid TumorsTerminatedNCT02440685Phase 1/2Results posted
- CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or LymphomaCompletedNCT02424968Phase 2Results posted
- A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCLCompletedNCT02423291Phase 2Results posted
- Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell LymphomaTerminatedNCT02420210Phase 2Results posted
- Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCLCompletedNCT02399085Phase 2Results posted
- BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCLTerminatedNCT02366663Phase 3Results posted
- Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCLTerminatedNCT02361346Phase 1/2Results posted
- Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin LymphomaCompletedNCT02348216Phase 1/2Results posted
- Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT02332980Phase 2Results posted
- Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell LymphomaCompletedNCT02285062Phase 3Results posted
- Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular LymphomaTerminatedNCT02282358Phase 1/2Results posted
- Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell LymphomaTerminatedNCT02272686Phase 2Results posted
- Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell LymphomasCompletedNCT02271945Phase 1/2Results posted
- Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's LymphomaCompletedNCT02268045Phase 3Results posted
- Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell LymphomaTerminatedNCT02266147Phase 1/2Results posted
- Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell LymphomaCompletedNCT02257242Phase 1Results posted
- A Phase I/II Study of Intratumoral Injection of SD-101CompletedNCT02254772Phase 1/2Results posted
- An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's LymphomaTerminatedNCT02253992Phase 1/2Results posted
- Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P MutationCompletedNCT02252146Phase 1/2Results posted
- Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT02242045Phase 1Results posted
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)CompletedNCT02208037Phase 2Results posted
- Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin LymphomaCompletedNCT02207062Phase 2Results posted
- Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02199184Phase 2Results posted
- Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHLTerminatedNCT02151903Phase 1/2Results posted
- Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell LymphomaCompletedNCT02142049Phase 1/2Results posted
- ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCLCompletedNCT02141451Phase 1/2Results posted
- Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell LymphomaCompletedNCT02112526Phase 1Results posted
- A Phase II Study of Doxycycline in Relapsed NHLTerminatedNCT02086591Phase 2Results posted
- A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple MyelomaTerminatedNCT02082977Phase 1Results posted
- Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02077166Phase 1/2Results posted
- A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCLCompletedNCT02055820Phase 1/2Results posted
- Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT02037256Not applicableResults posted
- Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma PatientsCompletedNCT01994850Phase 1/2Results posted
- Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLCompletedNCT01994382Phase 1/2Results posted
- A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's LymphomaCompletedNCT01992653Phase 1/2Results posted
- Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular LymphomaCompletedNCT01980654Phase 2Results posted
- A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)CompletedNCT01953692Phase 1Results posted
- Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT01925612Phase 2Results posted
- Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid MalignanciesCompletedNCT01921387Phase 1/2Results posted
- Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesCompletedNCT01919619Phase 2Results posted
- Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCLCompletedNCT01897571Phase 1/2Results posted
- A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHLTerminatedNCT01874288Phase 1/2Results posted
- Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic LeukemiaCompletedNCT01865617Phase 1/2Results posted
- A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaCompletedNCT01855750Phase 3Results posted
- Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01839916Phase 2Results posted
- Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT01812005Phase 2Results posted
- Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
- A Phase I Trial of AZD3965 in Patients With Advanced CancerCompletedNCT01791595Phase 1Results posted
- Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
- Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedNCT01769222Phase 1Results posted
- Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT01741792Phase 2Results posted
- A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3aCompletedNCT01724021Phase 3Results posted
- Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell LymphomaCompletedNCT01718691Phase 2Results posted